Interestingly, peginterferon lambda-1a led to markedly fewer cases of influenza-like symptoms, leukopenia and dose-reductions than peginterferon alpha-2a, though it did cause more hepatobiliary events consistent with IFNLR1 expression in hepatocytes and liver endothelial cells (59). This evidence concerns the gene IFNLR1 and influenza.